A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application
| العنوان: | A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application |
|---|---|
| المؤلفون: | Reshma Mahtani, Lin Zhan, Cheryl Fletcher Jones, Lynn McRoy, Maria Reynolds, Kelly Hollis, Jeffrey B. Hargis, James A. Kaye, Debanjali Mitra, Dawn Odom, David J. Richardson |
| المصدر: | Breast Cancer Research and Treatment |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 050103 clinical psychology, Cancer Research, medicine.medical_specialty, Longitudinal study, Receptor, ErbB-2, Breast Neoplasms, Palbociclib, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Quality of life, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 0501 psychology and cognitive sciences, Longitudinal Studies, Patient Reported Outcome Measures, Prospective Studies, Patient-reported outcomes, business.industry, Medical record, 05 social sciences, Metastatic breast cancer, medicine.disease, Mobile Applications, Clinical Trial, Family life, Mood, Receptors, Estrogen, Oncology, 030220 oncology & carcinogenesis, Quality of Life, Female, Advanced breast cancer, business, Cyclin-dependent kinase 4/6 |
| الوصف: | PurposeTo assess and describe patient-reported outcomes (PROs) in women with locally advanced/unresectable or metastatic breast cancer (aBC/mBC) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) status receiving palbociclib combination therapy in a US real-world setting.MethodsA prospective, noninterventional, multicenter longitudinal study was conducted in US patients initiating treatment with palbociclib combination therapy for HR + /HER2 − aBC/mBC. PRO data (SF-12; CES-D-10; mood; pain; fatigue; interference of aBC/mBC or its treatment on family life, social life, physical activity, energy, and productivity; overall health rating; and quality of life [QOL]) were collected via a custom-developed mobile application at daily, weekly, and cycle-based intervals. Patient medical information (demographics, clinical characteristics, treatment information, and adverse events) was collected from medical records at baseline and at the end of the 6-month follow-up period.ResultsPatients’ general health status (SF-12) remained consistent throughout treatment and was generally consistent with published norms for individuals diagnosed with cancer. The presence of depression (CES-D-10) was low and did not change substantially over time. Mean pain and fatigue scores using an 11-point numeric rating scale were low and remained stable. Patients, on average, reported neutral or positive moods. Patient-reported QOL and overall health was primarily “Good,” “Very good,” or “Excellent.” Findings were consistent regardless of patient experience with neutropenia.ConclusionsPatients treated with palbociclib, on average, reported consistently low levels of pain and fatigue as well as good QOL and overall health that remained stable throughout the first 6 months of treatment regardless of episodes of neutropenia. |
| تدمد: | 1573-7217 0167-6806 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c262330162a85e1b7360e4d2581ea3f https://doi.org/10.1007/s10549-020-06082-7 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....4c262330162a85e1b7360e4d2581ea3f |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 15737217 01676806 |
|---|